ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Account Payables
Amounts the company owes suppliers for goods and services received.
ADC Therapeutics S.A.NYSE: ADCT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 66.0% from a year ago
Account payables stood at $5.3M at the end of Q1 FY2026, down 66.0% from a year earlier and down 42.3% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Account payables amounted to 1.8% of total assets at the end of Q1 FY2026, down 3.9 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -66.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 9.18M USD
- Year-over-year change
- -49.1%
- 4-year CAGR
- -6.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.18M | -49.1% |
| FY2024 | 2024-12-31 | 18.03M | +15.8% |
| FY2023 | 2023-12-31 | 15.57M | +26.1% |
| FY2022 | 2022-12-31 | 12.35M | +2.2% |
| FY2021 | 2021-12-31 | 12.08M | — |
Account Payables vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's Mar 2026 account payables of $5.3M is the 6th highest of the 10 companies compared; the peer median is $5.37M.
- Its year-over-year change of -66.0% is the 9th highest of 10, against a peer median of -5.5%.
- Account payables amounts to 1.8% of total assets for ADCT, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.69M | +253.9% | +49.8% | 2.9% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $12.8M | -14.6% | +80.4% | 2.3% |
| Mar 2026 | $5.97M | -46.3% | +14.3% | 0.9% | |
| Mar 2026 | $5.57M | +179.0% | -0.7% | 5.1% | |
| Mar 2026 | $5.37M | +21.6% | -7.3% | 1.9% | |
| Mar 2026 | $5.3M | -66.0% | -9.4% | 1.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $5.06M | +380.7% | -22.1% | 3.3% |
| Mar 2026 | $3M | -72.0% | -33.3% | 1.1% | |
| Mar 2026 | $1.87M | -58.0% | +79.7% | 0.4% | |
| Mar 2026 | $1.79M | -5.5% | -25.4% | 0.8% | |
| Peer median (excluding ADCT) | $5.37M | -5.5% | -0.7% | 1.9% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 466.54M | 326.44M | 278.6M | 250.87M | 261.34M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 31.06M | 72.97M | 25.18M | 20.32M | 29.12M |
| Inventory | 11.12M | 12.07M | 16.18M | 18.39M | 4.18M |
| Other Current Assets | 1.11M | 199K | 5.99M | 9.45M | 11.7M |
| Total Current Assets | 525.18M | 434.98M | 336.29M | 307.39M | 306.34M |
| Property, Plant & Equipment (Net) | 11.23M | 10.26M | 16.13M | 13.43M | 1.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 13.58M | 14.36M | 0 | 0 | 0 |
| Long-term Investments | 41.24M | 7.61M | 1.65M | 0 | 0 |
| Tax Assets | 26.05M | 37.1M | 0 | 0 | 0 |
| Other Non-current Assets | 693K | (13.46M) | 711K | 1.16M | 15.52M |
| Total Non-current Assets | 92.79M | 55.88M | 18.49M | 14.59M | 16.82M |
| Total Assets | 617.97M | 490.86M | 354.78M | 321.98M | 323.15M |
| Account Payables | 12.08M | 12.35M | 15.57M | 18.03M | 9.18M |
| Short-term Debt | 6.58M | 12.47M | 0 | 0 | 3M |
| Tax Payables | 3.75M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 14.11M | 4.08M | 37.94M | 47.47M | 57.99M |
| Total Current Liabilities | 73.94M | 81.94M | 67.67M | 80.47M | 70.16M |
| Long-term Debt | 125.1M | 109.71M | 112.73M | 113.63M | 436.01M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 23.54M | 23.54M | 0 | 320.09M | 0 |
| Other Non-current Liabilities | 222.32M | 189.65M | 312.45M | 2.43M | 2.81M |
| Total Non-current Liabilities | 377.95M | 329.47M | 435.36M | 444.15M | 438.82M |
| Total Liabilities | 451.88M | 411.41M | 503.03M | 524.62M | 508.98M |
| Common Stock | 6.45M | 7.31M | 7.31M | 8.43M | 11.08M |
| Retained Earnings | (924.89M) | (1.1B) | (1.34B) | (1.49B) | (1.64B) |
| Accumulated OCI | 102.83M | 1.82M | (93K) | (1.42M) | (517K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 166.09M | 79.45M | (148.25M) | (202.64M) | (185.83M) |
| Total Debt | 139.7M | 129.85M | 124.38M | 123M | 439.01M |
| Net Debt | (326.85M) | (196.59M) | (154.22M) | (127.87M) | 177.67M |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.